Dabigatran and Lapatinib: Interaction Details

Brand names
Lapatinib
Tykerb
Dabigatran
Pradaxa
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

What Happens When You Take Dabigatran With Lapatinib

What can happen when they are taken together (rated Major)

Increased dabigatran exposure and an increased risk of bleeding

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Because combining dabigatran with a can raise dabigatran exposure and the likelihood of bleeding, the two should generally not be given together,2 and this is especially true for patients with impairment. For adults taking dabigatran capsules to lower the risk of stroke and systemic embolism in non-valvular atrial fibrillation, should be avoided when CrCl is 15 to 30 mL/min.

Concomitant use should likewise be avoided when CrCl is below 50 mL/min in adults receiving dabigatran capsules to treat DVT or pulmonary embolism (PE), to reduce the risk of their recurrence, or for their prophylaxis following hip surgery. When CrCl is 50 mL/min or higher, the doses should be given several hours apart for prophylaxis.

In pediatric patients, the combination of dabigatran and P-gp has not been studied, although it may raise dabigatran exposure.1 Whatever the level of kidney function, caution may be warranted when dabigatran is given alongside moderate to strong P-gp inhibitors.3

The Dabigatran and Lapatinib Interaction, Explained

Lapatinib (Tykerb) is a cancer medicine, and dabigatran (Pradaxa) is a that helps prevent dangerous clots. Your body normally uses a "pump" in the gut and kidneys to push dabigatran out. Lapatinib can slow that pump down, so more dabigatran may build up in your blood.

More dabigatran means a higher chance of bleeding, such as easy bruising, nosebleeds, bleeding gums, or dark stools. This matters even more if your kidneys don't work as well. The good news is that your care team can plan around this. Please talk with your pharmacist or doctor before taking these together, and don't stop either medicine on your own.

Mechanism: Lapatinib inhibits , reducing -mediated efflux of dabigatran (etexilate is a P-gp ), which may increase dabigatran exposure (/) and bleeding risk. Onset unspecified; evidence rated probable; severity major.

  • Generally avoid , particularly with impairment.
  • NVAF: avoid if CrCl 15 to 30 mL/min.
  • DVT/PE treatment, recurrence reduction, or post-hip surgery prophylaxis: avoid if CrCl <50 mL/min; if CrCl 50 mL/min or greater, separate doses by several hours for prophylaxis.
  • Caution with moderate to strong P-gp regardless of renal function; not studied in pediatrics.
  • Monitor renal function and for signs of bleeding.

See the 4 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Dabigatran and Lapatinib Interact

The likely mechanism

of -mediated efflux transport of dabigatran

In short: Lapatinib slows P-glycoprotein, a pump that moves dabigatran out of cells, so more dabigatran can stay in the body.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When One Drug Raises Another’s Level”, one chapter of our one-minute explainer. See how it works 

How to Manage the Dabigatran and Lapatinib Interaction

Because lapatinib can raise dabigatran levels, care teams usually try to avoid using these together, especially when kidney function is reduced. Your team will look at your kidney function and why you take dabigatran. In some situations they may choose a different option, and in others they may space the doses several hours apart and monitor you more closely.

  • Keep taking your medicines exactly as prescribed; don't stop or change them on your own.
  • Make sure your oncologist and the prescriber of your both know you take these.
  • Report unusual bruising, bleeding, blood in urine, or black stools right away.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Dabigatran or Lapatinib need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

2 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses

    A 76-year-old woman residing in a nursing home, who was receiving dabigatran 150 mg twice daily for bilateral lower extremity DVTs along with low-dose quiNIDine (10 mg twice daily) for an unknown indication, was hospitalized with abdominal pain and rectal bleeding. Admission evaluation revealed anemia (Hb, 4.9 g/dL), coagulopathy (thrombin time (TT) greater than 60 seconds), acute kidney injury (SCr of 2 mg/dL; baseline 0.8 mg/dL), and an elevated BUN of 90 mg/dL.

    The diagnosis was acute blood loss anemia secondary to lower bleeding, likely related to dabigatran use. Hemodialysis was not started because of the bleeding risk associated with catheter placement.

    Transfusion measures and idaruCIZUmab administration initially normalized her Hb (8.2 g/dL) and TT (14.3 seconds); however, she rebled, and the TT was again greater than 60 seconds on repeat testing approximately 20 hours after idaruCIZUmab was given. She required a 10-day hospitalization for persistent coagulopathy, rectal bleeding, and impairment, during which she received 2 further doses of idaruCIZUmab on hospital days 2 and 4, each of which normalized coagulation parameters only temporarily.

    Rectal bleeding persisted until day 5, when it began to improve, although TT stayed elevated until hospital day 9. Although renal impairment may have contributed to decreased dabigatran in this case, quiNIDine (a ) was considered to have contributed to the initially suspected supratherapeutic dabigatran levels.4

  2. Report 2 · Study title

    Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function

    A comparative effectiveness study in patients with nonvalvular atrial fibrillation and normal kidney function found that the overall bleeding rate was 52% higher (244.9 vs 158.4 per 1000 person-years; HR, 1.52; 95% CI, 1.05 to 2.2) when dabigatran was coadministered with verapamil or dilTIAZem (n=750) than when it was coadministered with amLODIPine (n=1316), and 43% higher (291.3 vs 199.7 per 1000 patient-years; HR, 1.43; 95% CI, 1.02 to 2) with dabigatran plus verapamil or dilTIAZem (n=764) than with metoprolol (n=1334). Compared with amLODIPine, dabigatran with verapamil or dilTIAZem was also associated with significant increases in overall () bleeding (HR, 2.16; 95% CI, 1.3 to 3.6), minor bleeding (HR, 1.56; 95% CI, 1.07 to 2.27), and GI minor bleeding (HR, 2.16; 95% CI, 1.29 to 3.63).

    Compared with metoprolol, dabigatran with verapamil or dilTIAZem was associated with significant increases in overall GI bleeding (HR, 2.32; 95% CI, 1.42 to 3.79), major/moderate bleeding (HR, 3.32; 1.54 to 7.16), major/moderate GI bleeding (HR, 5.49; 95% CI, 1.67 to 18.03), and GI minor bleeding (HR, 2.33; 95% CI, 1.42 to 3.82). The dabigatran dose was 150 mg twice daily. Caution may be warranted when dabigatran is coadministered with verapamil and dilTIAZem, and possibly with other moderate to strong , irrespective of kidney function.3

Dabigatran and Lapatinib: Common Questions

How serious is the Dabigatran and Lapatinib interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Dabigatran and Lapatinib interaction managed?

Because lapatinib can raise dabigatran levels, care teams usually try to avoid using these together, especially when kidney function is reduced. Your team will look at your kidney function and why you take dabigatran. In some situations they may choose a different option, and in others they may space the doses several hours apart and monitor you more closely. Keep taking your medicines exactly as… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "probable". Good supporting evidence, though not definitively proven.

Ask About the Dabigatran and Lapatinib Interaction

Ask in your own words about taking Dabigatran and Lapatinib together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (4)

  1. Product Information: PRADAXA(R) oral capsules, dabigatran etexilate oral capsules. Boehringer Ingelheim Pharmaceuticals Inc (per FDA), Ridgefield, CT, 2023. DailyMed
  2. Steffel J, Collins R, Antz M, et al: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021; 23(10):1612-1676.
  3. Pham P, Schmidt S, Lesko L, et al: Association of oral anticoagulants and verapamil or diltiazem with adverse bleeding events in patients with nonvalvular atrial fibrillation and normal kidney function. JAMA Netw Open 2020; 3(4):e203593-. DOI
  4. George S, Taburyanskaya M, & Lewis V: Probable drug-drug interaction between dabigatran and quinidine resulting in thrombin time rebound despite multiple idarucizumab doses. Blood Coagul Fibrinolysis 2019; 30(1):42-46. PubMed
Was this write-up helpful?

Other Serious Interactions of Dabigatran and Lapatinib

Also serious with Lapatinib

Also serious with Dabigatran

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Lapatinib

With Dabigatran

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven. This interaction.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.